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Summary
Protein kinase inhibitors are optimized to have high
affinity for their intended target(s) to elicit the desired
cellular effects. Here, we asked whether differences in
inhibitory sensitivity between two kinase signaling
pathways, controlled by the cyclin-dependent kinases
Cdk1 and Pho85, can be sufficient to allow for selec-
tive targeting of one pathway over the other. We
show the oxindole inhibitor GW297361 elicits a Pho85-
selective response in cells despite having a 20-fold
greater biochemical potency for Cdk1 in vitro. We
provide evidence that partial inhibition of Pho85 is
sufficient to activate Pho85-dependent signaling, but
partial inhibition of Cdk1 is not sufficient to block
Cdk1-dependent cell proliferation. Identification of
highly sensitive kinases may provide a means to
achieve selective perturbation of kinase signaling
pathways complementary to efforts to achieve maxi-
mal differences between in vitro IC50 values.
Introduction
Protein kinases couple external or internal signals to
specific outputs, such as gene transcription or activa-
tion of effector proteins. Inhibitors of protein kinases
are a key resource for development of molecularly tar-
geted therapeutics, as well as being important tools
for studying the cellular functions of protein kinases
[1–3]. The discovery of protein kinase inhibitors often
begins with optimization of in vitro potency and selec-
tivity by biochemical assays followed by cell-based
assays. It is now widely appreciated that a number of
factors within cells can greatly influence the cellular po-
tency of kinase inhibitors, including competition with
high cellular ATP concentrations, membrane permeabil-
ity, the presence of cellular phosphatases, and the
concentration of kinase substrates relative to different
kinases [4]. The current generation of kinase inhibitors
have been designed to bind their targets with low nano-
molar binding affinities and to have suitable pharma-
cokinetic properties to efficiently penetrate cells, effec-
tively mitigating the first two of these factors. However,
the effect of the latter two factors, as well as a host of
*Correspondence: shokat@cmp.ucsf.eduother cellular components, on kinase inhibitor efficacy
is difficult to predict, as they require a detailed under-
standing of the network properties of signal trans-
duction pathways. More specifically, these factors de-
termine the degree of coupling between the activity
of a given kinase and the activation or repression of
downstream biological responses.
The complex relationship between the level of kinase
activity and an elicited cellular response has parallels to
well-established examples in receptor pharmacology,
where substoichiometric receptor occupancy by an ag-
onist can be sufficient to elicit full activation of the path-
way [5, 6]. Thus, agonist efficacy is not solely dependent
on the affinity of the agonist for a given receptor. Simi-
larly, protein kinases often regulate cellular responses
that are switch-like in nature. The level of kinase activity
necessary to propagate a signal in a cell can be thought
of as the intrinsic sensitivity of the pathway to perturba-
tions in kinase activity from, for example, a small-mole-
cule inhibitor. In principle, this pathway sensitivity may
be a key factor in determining inhibitor efficacy, and
differences in the sensitivity of pathways governed by
different kinases may affect inhibitor target specificity.
Here, we asked whether differences in inhibitory sen-
sitivity between kinase signaling pathways can be suffi-
cient to allow for the selective targeting of one pathway
over another within cells. By using a chemical screen of
a small library of CDK inhibitors, we probed the inhibi-
tory sensitivity of two kinases, Cdk1 and Pho85, in
Saccharomyces cerevisiae. Cdk1 is an essential protein
kinase that regulates each cell cycle transition in yeast
[7]. Pho85, the most closely related kinase in the yeast
kinome to Cdk1, is not essential for normal cell prolifer-
ation, but regulates nutrient sensing and stress re-
sponses to phosphate deprivation [8]. Given that it is im-
practicable to determine the precise degree of inhibition
of a kinase within a cell, we reasoned that the identifica-
tion of inhibitors that show little or no in vitro selectivity
between these two kinases, yet elicit Cdk1- or Pho85-
selective responses within cells, would provide powerful
evidence of differences in pathway sensitivity between
these two kinases.
We report the identification of GW297361 [9], 1 (Fig-
ure 1A), an oxindole CDK inhibitor that elicits a Pho85-
selective response in cells despite having a 20-fold
greater biochemical potency for Cdk1 in vitro. We ex-
plored the molecular basis for this selectivity, and pro-
vide evidence that the Pho85 signaling pathway is highly
sensitive to perturbations in kinase activity. Thus, the
ability of 1 to inhibit Pho85, but not Cdk1, in vivo reveals
distinct sensitivities of these kinases to chemical inhibi-
tion. Systematic determination of the quantitative con-
tribution of each kinase in a pathway to its biological
output could reveal the optimal nodes to block cell sig-
naling by small-molecule kinase inhibitors.
Results
In order to measure the cellular effects of Cdk1 and
Pho85 inhibitors, we used a recently described strategy
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(A) Oxindole CDK inhibitors were screened in functional assays for inhibition of Cdk1 and Pho85. (Left) Halo assays of GW400426 (1-TEG) or
GW297361 (1) showing differential effects on cell proliferation of YRP1 yeast. A 10 ml aliquot of a 2 mM DMSO stock of each compound was
added to the disc. (Right) 1-TEG and 1 both induce nuclear localization of Pho4-GFP when added at 20 mM to YRP1 cells. Shown are fluores-
cence images overlaid with brightfield edge traces of the cells.
(B) 1-TEG induces cell cycle arrest in YRP1 cells with an EC50 = 20 mM, while 1 has no effect at concentrations up to 50 mM.
(C) Time course of Pho4-GFP assay as depicted in (A). 1-TEG and 1 are nearly indistinguishable at all time points.for determining the molecular targets of protein kinase
inhibitors [10]. In that work, we used a chemical genetic
method of potently and monospecifically inhibiting an
engineered kinase (an ‘‘analog-sensitive kinase’’), along
with microarray profiling and other cell-based assays,
to identify molecular biomarkers diagnostic of inhibition
of specific kinases. We show that the CDK inhibitor
GW400426, 1-TEG (TEG = tetraethyleneglycol; Fig-
ure 1B), inhibits both Cdk1 and Pho85 kinases in the
YRP1 drug-sensitized yeast strain background. 1-TEG
inhibits yeast cell proliferation with an EC50 of roughly
20 mM—an activity that is accounted for by its potent
inhibition of the essential kinase Cdk1 (IC50 = 35 nM).
1-TEG treatment also induces the nuclear localization
of the GFP-tagged transcription factor Pho4 by inhibit-
ing its phosphorylation by Pho85, thus providing a sensi-tive fluorescence-based assay to monitor inhibition of
Pho85.
We used these two cellular readouts to screen a small
library of oxindole inhibitors (see Figure S1A in the Sup-
plemental Data) originally developed as inhibitors of
mammalian CDK2 [9]. We identified 1 as a molecule
that showed activity in the Pho4-GFP localization assay
that was nearly indistinguishable from 1-TEG (Fig-
ure 1C). However, 1, despite sharing a high degree of
structural similarity to 1-TEG, did not inhibit yeast cell
proliferation as evaluated by halo assay (Figure 1B), sug-
gesting that it was not inhibiting Cdk1 within cells. We
confirmed these results by evaluating the ability of 1 to
affect cellular proliferation in liquid culture. At concen-
trations up to 50 mM, 1 did not measurably affect cell
proliferation (Figure 1C). Concentrations greater than
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straints.
Next, we assessed whether the observed cellular tar-
get specificity of 1 was reflected by its in vitro potency
against these two kinases. Surprisingly, we found that
1 is actually a more potent inhibitor of Cdk1 than
1-TEG (IC50,1 = 20 nM versus IC50,1-TEG = 35 nM). More-
over, while 1 also inhibits Pho85 (IC50 = 400 nM) more
potently than 1-TEG does (IC50 = 1.5 mM), it does so
20-fold less potently than it inhibits Cdk1. Thus, the in-
hibitory activity of 1 against these two kinases within
yeast cells is reversed from that predicted by in vitro bio-
chemical measurements. 1-TEG and 1 share very similar
IC50 values against a wide variety of human kinases (Fig-
ure S1C), suggesting that the inverted cellular target
specificity of 1 does not reflect an ability to bind kinases
in a significantly different orientation.
While cell proliferation reflects the final outcome of
Cdk1-mediated signal transduction within the cell, we
sought to understand in greater detail the cellular effects
elicited by 1. The regulation of cell proliferation by Cdk1
is a complex process involving the phosphorylation of
hundreds of substrates [11] that regulate the transcrip-
tion of cell-cycle genes. We therefore examined both
the global effects on gene transcription of 1 as well as
its impact on the phosphorylation of Orc6, a direct sub-
strate of Cdk1 [12].
We conducted whole-genome transcriptional profil-
ing and examined the effects of 1 treatment on the tran-
scription of a set of 213 genes whose expression is de-
pendent on Cdk1 activity [10]. 1-TEG strongly represses
the transcription of these genes (Figure 2A, lanes 4 and
5), to a similar degree as from monospecific inhibition of
Cdk1 (Cdk1-as1 strain, lane 6), while 1 has a much
weaker repressive effect on these genes (lanes 2 and
3). Similar results were obtained when we evaluated
the expression of several Cdk1-dependent genes (CLB2,
CDC20, HOF1) by quantitative PCR (Figure 2E).
In log phase cells, Orc6 migrates as two distinct phos-
phoisoforms on SDS-PAGE that are present at approxi-
mately equal levels. Upon inhibition of Cdk1 by 1-TEG,
the majority of the Orc6 is converted to the faster-
migrating isoform (lower:upper = 4:1) (Figure 2B). Upon
treatment of YRP1 cells with 1, an intermediate level of
the faster-migrating phosphoisoform was obtained
(lower:upper = 2:1). Thus, examination of both Cdk1-
dependent gene transcription and substrate phosphor-
ylation reveals that 1 partially inhibits Cdk1 within cells.
The fact that 1, unlike 1-TEG, is unable to block cell pro-
liferation suggests that cell cycle control by Cdk1 is buff-
ered against small changes in Cdk1-mediated phos-
phorylation and transcription.
Next, we evaluated the effect of 1 on Pho85-mediated
signaling by monitoring a set of Pho4-dependent genes
involved in the response to low phosphate conditions
that are induced upon inhibition of Pho85. We previously
found that 1-TEG treatment results in a modest induc-
tion in gene expression compared to monospecific inhi-
bition of Pho85 in a Pho85-as1 strain, consistent with its
observed IC50 value (1.5 mM) against Pho85 in vitro [10].
While 1 is a slightly better Pho85 inhibitor (IC50 = 400 nM)
in vitro than 1-TEG, it induces the transcription of these
genes to a similar degree (Figure 2C). These results,
along with the Pho4-GFP localization data, are consis-tent with 1 inhibiting Pho85 in cells to a similar or some-
what lesser degree compared to 1-TEG. Furthermore, it
is clear that inhibition of Pho85 by either 1-TEG or 1 is
incomplete, as comparison with a Pho85-as1 strain
treated with 1-NA-PP1 results in both a stronger tran-
scriptional and Pho4-localization response (Figures 2C
and 1D). This is most likely the result of the relative im-
permeability of the oxindole scaffold to the yeast cell
wall compared to the pyrazolo-pyrimidine scaffold of
PP1 derivatives [10].
One factor that might begin to explain the inverted tar-
get specificity of 1 is the relative cellular concentrations
of the two kinases within cells. If the concentration of
Pho85 was much greater than that of Cdk1, it could
compensate for the difference in biochemical affinity
[4]. However, quantitative measurements of the concen-
trations of these two kinases under identical growth
conditions to those in our experiments show that both
Cdk1 and Pho85 are present at nearly equal levels [13].
Moreover, this explanation would not account for the in-
hibition of both Cdk1 and Pho85 by 1-TEG, a molecule
with roughly equivalent in vitro potency to that of 1.
If the Pho85 signaling pathway was inherently more
sensitive to changes in catalytic activity than the Cdk1
pathway, the data could be explained, if 1-TEG was
able to achieve greater intracellular concentrations
than 1. Under this scenario, 1 reaches a steady-state
cellular concentration that is only high enough to acti-
vate Pho85 signaling, while being insufficient to fully in-
hibit Cdk1 and block cellular proliferation.
It is difficult to precisely evaluate the concentrations
of small molecules within cells due to the complex fac-
tors (permeability, efflux, subcellular localization, etc.)
involved [14]. Given the shared oxindole scaffold be-
tween 1-TEG and 1, we reasoned that the yeast generic
environmental stress response (ESR) [15] to the pres-
ence of foreign molecules might make a reasonable sur-
rogate marker to approximate the intracellular concen-
trations of these molecules. When we examined the
expression of genes involved in the ESR upon treatment
with 1-TEG or 1, we found that, at 20 mM, 1 had a slightly
diminished response in both induction and repression of
ESR genes (Figure 2D). At 40 mM, the responses of
1-TEG and 1 were very similar. These data suggest
that 1 may be less biovailable than 1-TEG. However,
the similarity in the ESR between 1-TEG at both concen-
trations, 1 at 40 mM and 1-NA-PP1 at 5–20 mM (data not
shown), suggests that the upper limit of the ESR has
been reached, and these markers are not suitable to
make conclusive judgments about the concentration of
the molecules within the cell.
Any enhanced bioavailability of 1-TEG could, in princi-
ple, be conferred due to a change in a physicochemical
property, such as the superior solubility in DMSO and
aqueous media of 1-TEG compared to 1. Alternatively,
it could result from a discrete molecular recognition
event mediated by the TEG moiety that results in en-
hanced bioactivity in yeast, such as inhibition of an ef-
flux pump or recognition by an importer. There is some
precedent for the latter scenario, as long-chain alkyl es-
ters of adenosine monophosphate (AMP) were found to
cause cytotoxic effects in yeast due to modulation of
a signaling pathway that activates a plasma membrane
proton pump [16]. The TEG group found on 1-TEG is
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(A) Cluster of 213 genes whose expression is repressed upon inhibition of Cdk1. Quantitation of mean log expression ratios is shown below
each column. 1 exhibits partial inhibition of Cdk1-dependent gene expression compared to full inhibition achieved by 1-TEG or in a Cdk1-as1
strain inhibited with 1-NA-PP1.
(B) Western blot quantitating Orc6 phosphoisoforms present in Cdk1-as1 or YRP1 cells following treatment for 15 min with DMSO, 1-NA-PP1,
or 1-TEG or 1. The effect of 1 is consistent with partial inhibition of Cdk1 within cells.
(C) Cluster of 27 genes whose expression is induced upon inhibition of Pho85. Both 1 and 1-TEG upregulate Pho4-dependent genes. Com-
parison to a Pho85-as1 strain inhibited with 1-NA-PP1 suggests partial inhibition of Pho85 by 1 and 1-TEG within cells. The columns are the
same as in (A).
(D) Effects of 1-TEG and 1 on expression of genes involved in the yeast ESR. A 20 mM treatment with 1 results in a milder response than 40 mM
1 or treatment with 1-TEG, providing indirect evidence that 1 has reduced bioavailability in YRP1 yeast.
(E) Quantitative PCR measurements of expression changes in three markers of Pho85 inhibition (SPL2, PHO11, PHO89) and Cdk1 inhibition
(CLB2, CDC20, HOF1) upon treatment of YRP1 yeast for 10 min with 1-TEG or 1. Values represent the change in expression compared to
DMSO treatment. For the washout experiment on the right, cells were treated with 1-TEG for 10 min, pelleted, and resuspended in fresh media
containing 1% DMSO for 10 min.a distinct SAR element in this series of molecules, as we
had found that all three molecules with antiproliferative
activity in our screen contained a similar polyethyleneglycol (PEG) moiety coupled to the sulfonamide moiety,
while molecules with other substituents did not (Fig-
ure S1B). PEGylation has been used to improve the
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403Figure 3. Probing the Molecular Basis for the Difference in Target Specificity between 1 and 1-TEG
(A) (i) TsCl, TEA, 210ºC; (ia) LiBr, NaHCO3 then H-1-NM, K2CO3, DMF; (ii) NaN3, TBAHS, DMF; (iii) H2, Pd/C, MeOH; (iii
a) FAM-SE, DMF. Further
synthesis details in Experimental Procedures.
(B) Halo assays showing effects on cellular proliferation of 1-NM-PP1-, 2-NM-PP1-, and 1-NM-TEG-treated Cdk1-as1 cells. In this series of
molecules, in vitro potency closely tracks the cellular efficacy.
(C) Neither TEG-Me nor TEG-F is able to penetrate the cell wall of YRP1 yeast. FDA treatments demonstrate compartmentalization of fluores-
cein molecules following hydrolysis of acetyl groups.pharmacokinetic properties of both proteins [17] and
small molecules [18].
In an attempt to distinguish between the two possibil-
ities, we synthesized TEG-based ‘‘molecular chimeras’’
to see if the TEG moiety would confer enhanced bioac-
tivity in yeast in a general fashion to small molecules.
We first asked if TEG could increase the cellular concen-
trations of a small molecule. We synthesized 1-NM-TEG,
a derivative of 1-NM-PP1 (Figure 3A). As 1-NM-PP1 is
already able to cross the yeast cell wall, we were in-
terested in seeing if attaching the TEG moiety would
enhance its potency against analog-sensitive kinases.Using a standard halo assay, we found that 1-NM-TEG
failed to suppress yeast cell proliferation as potently as
1-NM-PP1 when applied at the same concentration (Fig-
ure 3B, top). However, we also found that 1-NM-TEG
(IC50 = 240 nM) is a much weaker inhibitor than 1-NM-
PP1 (IC50 = 3 nM) of Cdk1-as1 in vitro, consistent with
known structure-activity relationships for PP1 analogs
[19]. Therefore, we asked whether 1-NM-TEG demon-
strated unusually high potency within cells given its
weaker in vitro potency. We assessed the inhibitory
properties of 2-NM-PP1, a molecule with an in vitro
potency against Cdk1-as1 very similar to 1-NM-TEG
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resulted in a halo virtually identical to that associated
with 1-NM-TEG treatment, demonstrating that in this
series of molecules, in vitro inhibitory potency translated
directly to in vivo efficacy (Figure 3B, bottom) irrespec-
tive of the TEG moiety. This result also rules out the pos-
sibility that the TEG moiety is generally toxic to yeast.
Next, we asked if TEG could by itself overcome the
impermeability of a cell membrane to a small molecule
by synthesizing a TEG-conjugated fluorescein fluoro-
phore (Figure 3A, TEG-F). Fluorescein is unable to cross
the cell wall of wild-type yeast or YRP1 yeast (data not
shown). We asked whether TEG-F would be able to
overcome this impermeability by treating YRP1 yeast
with either TEG-F or a methyl amide fluorescein control
compound (Me-F) at concentrations up to 100 mM and
visualizing the cells with fluorescence microscopy. As
a positive control to ensure we could detect cellular en-
try of fluorescein, we used a yeast-permeable form of
fluorescein, fluorescein diacetate (FDA). FDA is taken
up by yeast cells and hydrolyzed to the fluorescent
species within 15 min by intracellular esterases (Fig-
ure 3C). In contrast, we found that there were few, if
any, cells that took up either TEG-F or Me-F after
15 min (Figure 3C). After 45 min, the small (<5%) per-
centage of cells that demonstrated fluorescein uptake
appeared to be dead stationary phase cells that pre-
sumably had compromised membrane permeability.
Consistent with this notion, the fluorescence in these
cells did not become localized to discrete cellular com-
partments, as seen in the FDA-treated cells. At all con-
centrations, the cell permeability of Me-F and TEG-F
were indistinguishable. Collectively, these experiments
suggest that there appears to be no TEG-specific mo-
lecular recognition event that confers enhanced bioac-
tivity to 1-TEG over 1.
If the Pho85 signaling pathway was more sensitive to
changes in Pho85 catalytic activity through chemical in-
hibition than was the Cdk1 pathway, it might also be ex-
pected to recover more quickly upon removal of the
drug [20]. Therefore, we investigated the dynamic prop-
erties of the Pho85 and Cdk1 signaling pathways. We
treated YRP1 cells with 1-TEG for 10 min to induce
both Pho85 and Cdk1-dependent responses, and then
washed out the drug for 10 min. Quantitative PCR ex-
periments monitoring the expression of Pho85 and Cdk1-
dependent genes (SPL2, PHO11, PHO89,CLB2,CDC20,
HOF1) confirmed that, upon wash out, the Pho85 tran-
scriptional signature is quickly abrogated, whereas the
Cdk1 signature is sustained (Figure 2E, right). These
results demonstrate that the Pho85 signaling pathway
is rapidly switchable between activated and repressed
states.
Although there are other plausible explanations that
we cannot rule out at this time, our results are consistent
with a model in which the cellular target specificity of 1 in
budding yeast is governed by its poor bioavailability due
to its pharmacokinetic properties. Our data suggest that
partial inhibition of Pho85 by 1 or 1-TEG is sufficient
to induce a significant biological response. Thus, 1 is
able to activate the Pho85-mediated environmental
sensing response, but is unable to attain the cellular
concentrations necessary to achieve significant Cdk1
inhibition.One prediction of this model would be that it should
be possible to identify a dose at which 1-TEG would
have the same cellular effects as 1 (e.g., inhibition of
Pho85 but not of Cdk1). We were unable to identify
such a dose. Treatment of YRP1 cells with 5 mM 1-TEG
results in nearly no biological response as measured
by microarray profiling [10]. This may reflect the underly-
ing and often underappreciated complexity of cellular
permeability to small molecules. Cellular phenotypes
were only observed for the oxindole series of com-
pounds in the drug-sensitized yeast strain YRP1, which
contains disruptions of two genes encoding small-
molecule efflux pumps (SNQ2D, PDR5D) and one gene
(ERG6D) involved in the biosynthesis of ergosterol,
a key component of the cell membrane. Treatment of
wild-type strains (Figure S1D) and yeast strains harbor-
ing any two of the three gene disruptions in YRP1 (data
not shown) failed to elicit any cellular response. Thus,
even in YRP1 yeast, the concentration of oxindole-
based inhibitors, such as 1-TEG and 1, within the cell
may not correspond linearly to the concentration added
to the media. Recent studies have demonstrated that
estrogen, and perhaps other lipophilic hormones, rely
on active transport, not passive diffusion, to enter
mammalian cells. These revelations about such a well-
studied molecule illustrate that the mechanisms under-
lying small-molecule bioavailability are complex and
poorly understood [21].
Discussion
In this paper, we sought to address a fundamental ques-
tion in understanding the molecular basis for the cellular
effects of protein kinase inhibitors, the relationship be-
tween the level of kinase activity and the output of a sig-
nal transduction pathway. We asked whether we could
selectively target a protein kinase based on the inhibi-
tory sensitivity of its cellular signaling pathway to mod-
ulation of kinase activity rather than the relative binding
affinities of a small molecule to the kinases within a cell.
By comparison to the structurally similar inhibitor
1-TEG, whose cellular targets were well defined based
on previous studies by chemical genetic analysis in
our lab, we have identified 1 as a CDK inhibitor that
elicits specific Pho85-dependent responses within
yeast cells, thus exhibiting a dramatically different cellu-
lar specificity profile than predicted based on its in vitro
profile. While we can not rule out all possible explana-
tions for the cellular activity of 1, we believe that the
inverted target specificity of 1 is strong evidence that
kinase signaling pathways within cells are differentially
sensitive to levels of kinase activity. To our knowledge,
this is the first example of a kinase inhibitor to be shown
to achieve its target specificity using such a mechanism.
In the field of receptor pharmacology, the identifi-
cation of signaling pathways that achieve maximal re-
sponse upon substoichiometric occupancy by agonists
has led to the concept of ‘‘spare receptors,’’ with other
cellular components being the limiting factor in signal
transduction [22]. For protein kinases, differences in
pathway inhibitory sensitivity might be expected to lie
in the nature of the signal integration that occurs to con-
vert individual protein phosphorylation events into spe-
cific biological responses. For instance, in S. cerevisiae,
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Pathway Sensitivity
Model to explain cellular effects of 1-TEG
and 1 within the cell. The x and y axes
show the percent inhibition of Cdk1 and
Pho85, respectively. All values are for sche-
matic purposes only. The level of inhibition
of Pho85 necessary to induce Pho85 locali-
zation (w30%, shaded in red) is relatively
low compared to that necessary to block
cellular proliferation through inhibition of
Cdk1 (w75%, shaded in blue). 1-TEG is
able to block both kinases within yeast cells
and falls within the purple area. If an inhibitor
is dosed at a concentration to achieve >30%
inhibition of Pho85 and <75% inhibition of
Cdk1, than it would be able to selectively
inhibit Pho85, despite having no apparent
selectivity by in vitro biochemical assays
(as illustrated by 1).the phosphorylation of Sic1, an inhibitor of the Cdk1-Clb
CDK-cyclin complex, by Cdk1-Cln on more than six
phosphorylation sites has been shown to be a mecha-
nism by which yeast cells impose a switch-like response
at the G1-S transition [23]. In that study, degradation of
Sic1 was achieved if six or more, but not five or fewer, of
nine CDK phosphorylation sites were present, illustrat-
ing the precise tuning of biological responses to protein
kinase activity. Similarly, the extent of phosphorylation
of Pho4 on one to four phosphorylation sites by the
Pho85-Pho80 CDK-cyclin complex controls the tran-
scriptional efficiency of genes involved in the response
to various environmental stresses [24].
The cellular circuitry in which each kinase is embed-
ded is also likely to play an important role in pathway
sensitivity. The cell cycle transitions orchestrated by
Cdk1, through phosphorylation of hundreds of sub-
strates, are irreversible processes in which a significant
fraction of Cdk1 substrates are regulated by other
mechanisms aside from an opposing phosphatase,
such as proteolytic degradation [11]. In contrast, the
rapid reversibility of the Pho85-Pho4 pathway is consis-
tent with tight coupling to an as-yet unidentified cellular
phosphatase(s) in a relatively simple regulatory circuit.
We hypothesize that the precise cell cycle transitions
governed by Cdk1-cyclin complexes might have
evolved to be highly resistant to biological noise, and
therefore to chemical inhibition as well. This point is il-
lustrated by the inability of 1 to block cellular prolifera-
tion despite having a quantitatively significant effect
on Cdk1-mediated gene transcription and substrate
phosphorylation. Efficient adaptation to changes in thecellular environment might require that the Pho85 sig-
naling pathway respond to even small changes in cata-
lytic activity as a measure of fluctuations in extracellular
phosphate concentration [8]. As seen schematically in
Figure 4, differences in the level of inhibition necessary
to achieve a biological response for Pho85 or Cdk1 inhi-
bition would account for the cellular target specificity of
1 and 1-TEG.
The identification of hypersensitive kinase pathways
may play an important role in selecting targets for inhib-
itor design. These kinases may themselves be attractive
targets, or they may need to be included in counter-
screens in the process of lead optimization to minimize
off-target side effects. Identification of hypersensitive
pathways will require detailed quantitative analysis of
the role of kinase activation in downstream signaling.
Already, it is apparent that even closely related kinases
may have significant differences in their network proper-
ties and, therefore, may respond differently to pharma-
cological inhibition. For instance, elegant studies inXen-
opus oocytes have shown that activation of the MAP
kinase JNK by progesterone stimulation occurs in
a manner whereby, in a population of oocytes, each
individual oocyte either has full JNK activation or none
[25]. In contrast, a recent report demonstrates that
mammalian ERK MAP kinase activity increases in a
graded fashion in response to agonist, with subsequent
switch-like behavior regulated at the level of gene tran-
scription [26].
Our current efforts to elucidate the functions of pro-
tein kinases using chemical genetic analysis should
aid in the process of systematically identifying and
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Chemical tools, such as specific, covalent inhibitors of
protein kinases [27], combined with chemical genomic
profiling, may allow us to address these questions in
a quantitative fashion.
Significance
The use of small-molecule protein kinase inhibitors to
modulate signal transduction mediated by protein ki-
nases has become a key focus of biomedical research.
The ability to predict the cellular effects of kinase
inhibitors is dependent on understanding the true cel-
lular targets of a molecule. However, protein kinase
inhibitors are usually optimized against their intended
targets through in vitro biochemical assays. This
paper addresses a complementary aspect of inhibitor
target specificity; namely the intrinsic inhibitory sensi-
tivity of the cellular pathways controlled by a given ki-
nase. By using cellular readouts of the activity of the
closely related CDKs Cdk1 and Pho85, we screened a
library of oxindole CDK inhibitors and identified
GW297361 as a molecule that appears to inhibit Pho85
selectively within cells despite a 20-fold preference
for Cdk1 in vitro. This supports the hypothesis that
the environmental sensing Pho85 signaling pathway
is tuned to be highly responsive to changes in Pho85
activity levels, whereas Cdk1 signaling, whose func-
tion is to regulate the cell cycle, appears to be buffered
against partial inhibition of Cdk1. The existence of
‘‘hypersensitive’’ kinases may offer a new strategy to
target this class of signaling enzymes. The differential
inhibitory sensitivity of kinase signaling pathways
may account for a subset of situations where there is
a significant discrepancy between amolecule’s in vitro
specificity and its observed cellular activities.
Experimental Procedures
Chemical Synthesis
1-TEG, 1, 1-NA-PP1, 1-NM-PP1, and 4-(naphthalen-1-ylmethyl)-
1H-pyrazolo[3,4-d]pyrimidine were synthesized as previously de-
scribed [9, 28]. Methyl ether tetraethylene glycol amine was synthe-
sized as previously described [29]. To synthesize TEG-F and Me-F,
FAM-SE (1 eq) and methyl ether tetraethylene glycol amine (1.2 eq)
or methylamine (1.2 eq) were dissolved in DMF, and the reaction
was allowed to stir for 4 hr at room temperature. Following removal
of DMF in vacuo, the reaction products were purified by HPLC and
lyophilized. ESI/MS analysis confirmed formation of the expected
product.
1-NM-TEG was synthesized by reacting methyl ether tetraetylene
glycol tosylate with LiBr. The crude brominated product was cou-
pled to H-1-NM in DMF with K2CO3. Products were purified by
HPLC and lyophilized. ESI/MS analysis confirmed formation of the
expected product.
Strains and Plasmids
YRP1 was a gift from Karl Kulcher (Vienna University, Vienna, Aus-
tria). Pho85-as1, Cdk1-as1, and dual Cdk1-as1/Pho85-as1 have
been described previously [10, 30, 31].
Kinase IC50 Assays
Cdk1-Clb2 and Pho85-Pho80 kinase assays were performed as pre-
viously described to determine IC50 values for 1-TEG and 1 [30].
Orc6 Phosphorylation
Exponentially growing Cdk1-as1 or YRP1 cells were treated with ei-
ther DMSO, 1-NA-PP1, 1-TEG, or 1 for 15 min. Cellular proteins wereextracted into urea lysis buffer (20 mM Tris [ph 7.4], 7 M urea, 2 M
thiourea, 4% CHAPS, 1% DTT, 50 mM NaF, 80 mM BGP, 1 mM
Na3VO4, 1 mM PMSF), run out on SDS-PAGE, and blotted to nitrocel-
lulose. The blot was probed with a monoclonal antibody against
Orc6 (SB49, 1:1000) and visualized by ECL after probing with an
HRP-conjugated goat anti-mouse antibody (1:1500; Pierce). Densi-
tometry quantitation was done using ImageJ software (http://rsb.
info.nih.gov/ij/).
Pho4-GFP
Pho85-as1 or YRP1 cells carrying the Pho4-GFP plasmid were
grown under selection to an OD of 0.5 and treated with 5 mM
1-NA-PP1, 20 mM 1-TEG (YRP1), or 20 mM 1 (YRP1). Samples were
taken at each time point and analyzed with static microscopy. At
least 50 cells were counted for each treatment.
Microarray Analysis
Microarray preparation and experimental procedures were per-
formed, and clusters from Figure 2 were identified as previously de-
scribed [10]. Briefly, yeast cells of the appropriate strain were grown
to an OD of 0.7 and treated with either inhibitor or the equivalent vol-
ume of dimethyl sulfoxide for 10 min. Cells were collected by filtra-
tion and flash-frozen in liquid nitrogen. Yeast total RNA was isolated,
followed by selection for polyadenylated mRNA from 1 mg of total
RNA. First-strand cDNA synthesis was carried out in the presence
of a dNTP/amino-allyl-dUTP mixture. The cDNA from paired sam-
ples was then labeled with either Cy3 or Cy5 dyes and hybridized
to microarrays containing w93% of yeast ORFs. Fluorescence ra-
tios were obtained with an Axon 4000A scanner. Each experiment
was done in replicate with Cy3 and Cy5 labeling reversed between
inhibitor and DMSO treatments in the replicate experiments. ‘‘Dye-
flipped’’ expression ratios were inverted and then averaged in
log-space with their nonflipped counterparts. To identify functional
clusters of genes as depicted in Figure 2A, expression ratios were
converted to log-space and the data set was filtered to include
genes whose expression changed by 1.6-fold or more in at least
two experiments. Genes were clustered with Cluster 3.0 software
(http://bonsai.ims.u-tokyo.ac.jp/wmdehoon/software/cluster/manual/)
by average-linkage hierarchical clustering.
Quantitative PCR
Sequences for 50-30 and 30-50 primers were as follows: ACT1: TC
ACTATTGGTAACGAAAGATTCAG, AAGCCAAGATAGAACCACCAA
TCCA. SPL2: AGAGTGCAGGAGGCTCAATC, TCGTCAATGACACAG
TCGTTC. PHO11: TCCAGTGTTCCAATGACACC, AGTTACTGACGC
TGCTGACG. PHO89: TCGGTTCTCCAAGCCATTAC, AAGGCAACA
CCACCATAAGC. CLB2: ATCAACAGCCGCACAAGAG, CATGCTGG
ATTATCTCCTTCG. CDC20: TGTGGAATGCCACCACTG, AATGAA
CCGATACGGACACC. HOF1: AACCAAGGCCGATTGTTG, GGCCA
TTGAACTTACGGATG.
Yeast log-phase cultures were treated with DMSO, 20 mM 1-TEG,
or 20 mM 1 for 10 min, harvested by centrifugation, and frozen at
280ºC. RNA was isolated by hot phenol/chloroform extraction. A
total of 1 mg of RNA was resuspended in a total volume of 10 ml
with 250 nM of 30-50 primer and heated to 70ºC for 10 min. The re-
verse transcription was carried out with StrataScript enzyme (Strata-
gene), according to the manufacturer’s instructions, at 50ºC for
45 min. Following ethanol precipitation, reaction products were
amplified in a GeneMachines (MJ Research) thermal cycler in the
presence of SYBR Green dye (Molecular Probes). Quantitation was
carried out by first measuring cycle threshold values in duplicate
from a dilution series spanning four orders of magnitude of a stan-
dard template. Cycle threshold values were measured in duplicate
from drug-treated and DMSO-treated samples and verified to fall
within the linear range of the standard series. Measured values
were normalized to ACT1 levels, which were found by microarray
analysis to be unchanged following drug or DMSO treatment.
Supplemental Data
Supplemental Data, including supplemental figures, are available
online at http://www.chembiol.com/cgi/content/full/13/4/399/DC1/.
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